|
![]() |
|
|
Restoril: profile and news
Cover Story: Can't fall asleep? May 15, 2006 Xanax: Covered or Not Covered? Apr 19, 2006 New weapons in travelers' round-the-clock jet-lag fight Apr 21, 2006 Addiction devastates two families Apr 25, 2006 Other information Indication For the short-term treatment of insomnia (generally 7-10 days). Pharmacology Temazepam is a benzodiazepine used as a hypnotic agent in the management of insomnia. Temazepam produces CNS depression at limbic, thalamic, and hypothalamic levels of the CNS. Temazepam increases the affinity of the neurotransmitter gamma-aminobutyric acid (GABA) for GABA receptors by binding to benzodiazepine receptors. Results are sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action. Mechanism Of Action Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Drug Category Anti-anxiety Agents; Adjuvants, Anesthesia; Benzodiazepines; GABA Modulators; ATC:N05CD07 Brand Names/Synonyms Apo-Temazepam; Cerepax; Crisonar; ER 115; Euhypnos; Euipnos; Gelthix; Hydroxydiazepam; K-3917; Levanxene; Levanxol; Levanzene; Mabertin; Methyloxazepam; N-Methyloxazepam; Normison; Novo-Temazepam; Oxydiazepam; Perdorm; Planum; Remestan; Restoril; Signopam; Temaz; Temazepam; WY 2917; Wy-3917 Dosage Forms CAPSULE (7.5 mg, 15 mg, and 30 mg) Absorption Well absorbed, minimal first-pass metabolism. Interactions Interactions for Temazepam: The pharmacokinetic profile of temazepam does not appear to be altered by orally administered cimetidine dosed according to labeling. Chemical IUPAC Name 10-chloro-4-hydroxy-6-methyl-2-phenyl-3,6-diazabicyclo[5.4.0]undeca-2,8,10,12-tetraen-5-one Chemical Formula C16H13ClN2O2 Half Life 10-20 hours Drug Type Approved Drug # Accession No APRD00676 CAS Registry Number 846-50-4 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |